Dermisonics Financial Statements From 2010 to 2026

Dermisonics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Dermisonics' valuation are provided below:
Market Capitalization
1.9 K
Earnings Share
(0.44)
We have found ninety-six available fundamental signals for Dermisonics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Dermisonics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The Dermisonics' current Market Cap is estimated to increase to about 15.4 M. The Dermisonics' current Enterprise Value is estimated to increase to about 17.2 M
Check Dermisonics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermisonics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 3.8 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.04. Dermisonics financial statements analysis is a perfect complement when working with Dermisonics Valuation or Volatility modules.
  
Build AI portfolio with Dermisonics Stock
Check out the analysis of Dermisonics Correlation against competitors.
For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.

Dermisonics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.4 M23.1 M18.9 M
Slightly volatile
Total Current Liabilities4.7 M4.5 M3.8 M
Slightly volatile
Total Stockholder Equity13.1 M18 M14.7 M
Slightly volatile
Accounts Payable308.5 K440.5 K360.1 K
Slightly volatile
Cash178.4 K145 K123 K
Slightly volatile
Good Will7.6 K8.6 K9.3 K
Slightly volatile
Total Liabilities3.3 M5.1 M4.2 M
Slightly volatile
Total Current Assets329.4 K613 K494.6 K
Slightly volatile
Intangible Assets16.1 M22.4 M18.3 M
Slightly volatile
Common Stock53.9 K43.6 K49.2 K
Slightly volatile
Property Plant Equipment1.9 K3.5 K2.8 K
Slightly volatile
Other Current Liabilities300 K337.5 K368.4 K
Slightly volatile
Long Term Debt432.1 K454.9 K542.4 K
Slightly volatile
Other Stockholder Equity6426761.2 K
Slightly volatile
Short and Long Term Debt1.6 M2.9 M2.4 M
Pretty Stable
Short Term Debt1.6 M2.9 M2.4 M
Pretty Stable
Other Liabilities50.6 K70.9 K59.7 K
Slightly volatile
Other Assets73.2 K80.1 K87.8 K
Slightly volatile
Other Current Assets491.4 K468 K391.9 K
Slightly volatile
Deferred Long Term Liabilities73.2 K80.1 K87.8 K
Slightly volatile

Dermisonics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative3.8 M4.7 M3.9 M
Slightly volatile
Total Operating Expenses3.8 M4.7 M3.9 M
Slightly volatile
Non Recurring293.7 K330.4 K360.6 K
Slightly volatile

Dermisonics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock350.3 K567.7 K475.9 K
Pretty Stable
Depreciation264 K251.4 K211.2 K
Slightly volatile
Capital Expenditures2.4 K2.7 KK
Slightly volatile
Total Cash From Financing ActivitiesM1.2 M1.1 M
Slightly volatile
Change To NetincomeM3.5 M3.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio1.041.110.6835
Slightly volatile
Book Value Per Share0.370.320.3335
Slightly volatile
Capex To Depreciation35.2739.6843.3098
Slightly volatile
PB Ratio1.041.110.6835
Slightly volatile
Cash Per Share0.00320.00260.0027
Slightly volatile
Income Quality0.370.30.304
Slightly volatile
Intangibles To Total Assets0.760.870.9464
Slightly volatile
Current Ratio0.260.160.1604
Pretty Stable
Shareholders Equity Per Share0.370.320.3335
Slightly volatile
Debt To Equity0.160.180.1937
Very volatile
Capex Per Share1.0E-41.0E-40.0021
Slightly volatile
Interest Debt Per Share0.07320.07620.0785
Slightly volatile
Debt To Assets0.130.140.1514
Pretty Stable
Price Book Value Ratio1.041.110.6835
Slightly volatile
Company Equity Multiplier1.41.481.306
Slightly volatile
Long Term Debt To Capitalization0.03430.03610.0342
Slightly volatile
Total Debt To Capitalization0.130.150.1615
Pretty Stable
Debt Equity Ratio0.160.180.1937
Very volatile
Quick Ratio0.260.160.1604
Pretty Stable
Cash Ratio0.03530.03720.054
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.4842
Slightly volatile
Price To Book Ratio1.041.110.6835
Slightly volatile
Debt Ratio0.130.140.1514
Pretty Stable
Price Fair Value1.041.110.6835
Slightly volatile

Dermisonics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.4 M13.4 M14.3 M
Slightly volatile
Enterprise Value17.2 M16.1 M17 M
Slightly volatile

About Dermisonics Financial Statements

Investors use fundamental indicators, such as Dermisonics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Dermisonics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year

Currently Active Assets on Macroaxis

When determining whether Dermisonics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermisonics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermisonics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermisonics Stock:
Check out the analysis of Dermisonics Correlation against competitors.
For more detail on how to invest in Dermisonics Stock please use our How to Invest in Dermisonics guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is there potential for Medical Devices market expansion? Will Dermisonics introduce new products? Factors like these will boost the valuation of Dermisonics. Projected growth potential of Dermisonics fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dermisonics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.44)
Return On Assets
(0.12)
Return On Equity
(3.92)
Investors evaluate Dermisonics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Dermisonics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Dermisonics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Dermisonics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermisonics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Dermisonics' market price signifies the transaction level at which participants voluntarily complete trades.